Cabozantinib with nivolumab and ipilimumab for untreated intermediate- or poor-risk advanced renal cell carcinoma [ID6330]

  • In development
  • GID-TA11433
  • Expected publication date: TBC

NIHRIO BN: 27428-Cabozantinib-in-Combination-with-Nivolumab-and-Ipilimumab-for-Renal-Cell-Carcinoma-V1.0-MAY2023-NON-CONF.pdf (nihr.ac.uk)